// App-Quantinova.ai

790 : A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Researchers

Presenter

  • Matthew Krebs

Principal Investigators

  • Margarita Majem

  • Enriqueta Felip

  • Martin Forster

  • Bernard Doger

  • Tim Clay

  • Enric Carcereny

  • Julio Peguero

  • Leora Horn

  • Pawan Bajaj

  • Patricia Roxburgh

  • Chrystelle Brignone

  • Christian Mueller

  • Frederic Triebel

Medical Centers

  • The Christie NHS Foundation Trust, Manchester, Manchester, UK

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • University College London, London, UK

  • Fundacion Jimenez Diaz, Madrid, Spain

  • St John of God Hospital, Perth, Australia

  • Institut Catal dOncologia Badalona, Badalona, Spain

  • Oncology Consultants, P.A., Houston, Texas, USA

  • Vanderbilt University Medical Center, Nashville, TN

  • Tasman Oncology Research, Queensland, Australia

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Immutep S.A.S., Paris, France

  • Immutep, Berlin, Germany

Locations

  • United Kingdom

  • Spain

  • Australia

  • United States

  • France

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • EDP 202

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved